Zogenix pays $250M upfront for startup Modis buyout by Ben Adams Monday, August 26, 2019 As fairy-tale biotech stories go, this is up there.
Zogenix data blunder trips up FDA filing for epilepsy drug Fintepla by Amirah Al Idrus Tuesday, April 9, 2019 The FDA has refused to review the new drug application for Zogenix's Fintepla because of missing and incomplete data.
Chasing GW, Zogenix scores a win in second Dravet phase 3 by Nick Paul Taylor Thursday, July 12, 2018 The efficacy and safety profile set the company up to compete with GW Pharmaceuticals in Dravet, sending Zogenix stock up 18% in premarket trading.
